Literature DB >> 10642268

Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.

P M Okin1, S Jern, R B Devereux, S E Kjeldsen, B Dahlöf.   

Abstract

Obesity may limit sensitivity of ECG voltage criteria for left ventricular hypertrophy (LVH) because of the attenuating effects of increased body mass on precordial voltages. However, obesity is associated with an increased prevalence of anatomic LVH, making more accurate ECG criteria in obese patients a clinical priority. ECG LVH by Cornell voltage-duration product and/or Sokolow-Lyon voltage criteria was used to select patients for the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Clinical and ECG data were available in 8417 patients (54% women; mean age, 67+/-7 years); 2519 were overweight and 1573 were obese by gender-specific body mass index criteria. Increased body mass index had significant but directionally opposite effects on ECG LVH by these 2 criteria. Compared with normal-weight patients, obese and overweight patients had lower Sokolow-Lyon voltage and a lower prevalence of ECG LVH by Sokolow-Lyon criteria (10.9% versus 16.2% versus 31.4%; P<0.001). In contrast, obese and overweight patients had higher mean values of the Cornell product and higher prevalences of ECG LVH by this criterion (75.1% versus 69.9% versus 60.7%; P<0. 001). After adjustment for age, gender, race, myocardial infarction, and diastolic and pulse pressure with the use of logistic regression analysis, increased body mass remained highly predictive of the presence of ECG LVH. Compared with normal-weight patients, obese patients had a >2-fold higher risk of ECG LVH by the Cornell product but a 4-fold lower risk of ECG LVH by Sokolow-Lyon voltage; overweight status was associated with intermediate risks, with a 151% greater likelihood of ECG LVH by the Cornell product but only 44% of the risk of LVH by Sokolow-Lyon voltage criteria compared with normal-weight individuals. Thus, Sokolow-Lyon voltage criteria underestimate the prevalence of anatomic LVH in the presence of obesity, whereas Cornell product criteria for ECG LVH appear to provide a more accurate measure of LVH in obese and overweight patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642268     DOI: 10.1161/01.hyp.35.1.13

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  29 in total

1.  Diagnostic performance of electrocardiographic criteria for left ventricular hypertrophy among various body mass index groups compared to diagnosis by cardiac magnetic resonance imaging.

Authors:  Veerawat Nomsawadi; Rungroj Krittayaphong
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-02-05       Impact factor: 1.468

2.  Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Authors:  G Boner; M E Cooper; K McCarroll; B M Brenner; D de Zeeuw; P R Kowey; S Shahinfar; T Dickson; R S Crow; H-H Parving
Journal:  Diabetologia       Date:  2005-08-05       Impact factor: 10.122

3.  The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus.

Authors:  A Dawson; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2005-08-11       Impact factor: 10.122

4.  Long-Term Effects of an Intensive Lifestyle Intervention on Electrocardiographic Criteria for Left Ventricular Hypertrophy: The Look AHEAD Trial.

Authors:  Tina E Brinkley; Andrea Anderson; Elsayed Z Soliman; Alain G Bertoni; Frank Greenway; William C Knowler; Stephen P Glasser; Edward S Horton; Mark A Espeland
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

Review 5.  End organ damage in hypertension.

Authors:  Roland E Schmieder
Journal:  Dtsch Arztebl Int       Date:  2010-12-10       Impact factor: 5.594

6.  Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

Authors:  L Julian Haywood; Barry R Davis; Linda B Piller; Lara M Simpson; Alokananda Ghosh; Paula T Einhorn; Charles E Ford; Jeffrey L Probstfield; Elsayed Z Soliman; Jackson T Wright
Journal:  J Natl Med Assoc       Date:  2017-07-24       Impact factor: 1.798

7.  Electrocardiographic signs of left ventricular hypertrophy in obese patients: what criteria should be used?

Authors:  Giuseppe Germano
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-08-05

8.  Thresholds in the relationship between mortality and left ventricular hypertrophy defined by electrocardiography.

Authors:  Edward P Havranek; Caroline D B Emsermann; Desiree N Froshaug; Frederick A Masoudi; Mori J Krantz; Rebecca Hanratty; Raymond O Estacio; L Miriam Dickinson; John F Steiner
Journal:  J Electrocardiol       Date:  2008-03-14       Impact factor: 1.438

9.  Addition of highly sensitive troponin T and N-terminal pro-B-type natriuretic peptide to electrocardiography for detection of left ventricular hypertrophy: results from the Dallas Heart Study.

Authors:  Abelardo A Martinez-Rumayor; James A de Lemos; Anand K Rohatgi; Colby R Ayers; Tiffany M Powell-Wiley; Susan G Lakoski; Jarett D Berry; Amit Khera; Sandeep R Das
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

10.  Correlation relationship assessment between left ventricular hypertrophy voltage criteria and body mass index in 41,806 Swiss conscripts.

Authors:  Roger Abächerli; Lingchuan Zhou; Johann-Jakob Schmid; Richard Kobza; Bernhard Niggli; Franz Frey; Paul Erne
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-10       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.